Overturning Insurance Denials: What happens when your payer says no!?
You’ve all been there – your Payer denies you for:
Drugs
Specialist
Providers Procedures
2nd Opinions
What do you do next? How do you avoid hours on the phone? How do you beat the runaround?
We cover all types of payers, from Private and Obama Plans to Commercial and CMS (Medicaid and Medicare).
Ask the Experts: Gil Solomon, MD – Retired Family Physician and Health Plan Medical Director, and Allie Antonucci, CPC, Market Access and Reimbursement Professional, present and discuss. Dr. John Antonucci hosts the event.
AnCan would like to thank our sponsors who make these presentations possible. Those are Novartis, Blue Earth Diagnostics, Tealix, and Bayer.
If you know your family carries or is at risk for a germline/inhetited mutation, the game changes. It may not be a parent, sibling, or child that creates concern…watch out for aunts, uncles, nieces, nephews, even grandparents! Genetic Counselor and AnCan Advisory Board Member, Lindsey Byrne, MSCGC from NCCN/NCI The James CCC at Ohio State University, will lead you through the additional considerations to keep in mind if you face that situation. Including where to look and how to get others to test. Alongside her, we will have Dr. Pamela Munster, now at Stanford, who will present and discuss. We’ll also have a panel featuring some faces you are sure to recognize!
Predicting Radiation Side Effects – PROSTOX Webinar with interesting updates!
Last year, we presented a webinar on predicting Prostate Cancer Radiation Treatment side effects with PROSTOX before treatment begins. By analyzing your unique genetics, you can make smarter, more informed decisions to avoid side effects and safeguard your quality of life for years to come.
PROSTOX Standard (previously PROSTOX CFRT+) predicts late grade ≥2 toxicity from conventionally fractionated (CFRT) or moderately hypofractionated (MHFRT) radiation therapy for patients with localized prostate cancer. Together with PROSTOX Ultra, which is already available for patients considering stereotactic body radiation therapy (SBRT), the PROSTOX portfolio now provides risk assessment across a broader range of external beam radiation therapy (EBRT) types. We’ll discuss the updates and other patient concerns, such as insurance coverage and questions to bring to your doctors.
AnCan has long been perplexed by the prostate cancer category “non-metastatic Castrate Resistant” or even “non-metastatic Hormone Sensitive”. If PSA is rising after primary treatment but prior to hormone treatment, something’s going on, however, ‘micro-metastatic’. It’s like being just a little bit pregnant!!
This paper considers a new category, PSMA Positive Biochemically Recurrent – PSMA+ BCR. We circulated the paper to our Brains Trust and reached out to Dr. Ravi Madan at the National Cancer Institute (NCI) with a couple of questions. Dr Madan offered to meet with us along with his colleague, Dr. Melissa Abel. What resulted was this REMARKABLE video that could present many of our recurrent and advanced AnCan (& non-AnCan) participants with one of the most mind-blowing videos many have seen in a long time,
DO YOU REALLY NEED TREATMENT??
As the venerable and highly respected Dr. Paul Schellhammer said in the meeting, “it’s like listening 15 years ago to the folks who began to promote active surveillance ( in first line treatment)” Dr. Madan and Dr. Abel have collected solid data from around 150 patients that suggests men with slow PSA doubling times can “play the long game” as Dr. Ravi calls it, and defer active treatment when their disease recurs.
PLEASE watch this astonishing presentation, listen to some excellent observations and questions, and consider how it relates to your own situation. And spread the word to others. Dr. Madan’s and Dr. Abel’s NCI clinical trial can be found at https://www.clinicaltrials.gov/study/NCT05588128. Don’t immediately assume you’re not eligible before speaking with them… but you’ll have to watch the video to get their contact information.
Living with Visual Snow – a Therapist’s Perspective with Dr. Paula Hechinger
“My approach to Visual Snow Syndrome was born from my own journey from being a depressed and isolated mother of two to becoming a resilient psychoanalyst. Today, I not only help individuals navigate VSS but also support those facing a wide range of mental health challenges, including depression, bipolar disorder, anxiety, borderline personality disorder, trauma, and more. What once felt like a limitation became the foundation of my purpose to guide others toward healing with empathy, depth, and lived understanding.” -Dr. Paula Hechinger
Join us for a special presentation with Dr. Paula Hechinger, a psychoanalyst who is living with Visual Snow Syndrome. She shares her personal journey, insights, and practical tips for managing VSS. Click Here to view her personal testimony and presentation.
For a list of resources on Visual Snow Syndrome (VSS), click here.
